Introduction: C-reactive protein (CRP) value can identify the risk level for acute coronary syndrome (ACS). Ivabradine, a selective inhibitor of the funny current channel, reduces resting and exercise HR without affecting cardiac contractility or blood pressure.
Introduction
Measuring C-reactive protein (CRP) can identify the risk level for acute coronary syndrome (ACS). Likewise; reduced heart rate variability has been demonstrated to be the strongest independent predictor of progression of local coronary atherosclerosis [1] .
Funny current channels (I f ), are activated during the resting potential stage and accelerate diastolic depolarization of the sinus node and thus its pacemaker function [2] . Ivabradine, a selective inhibitor of the funny current channel, reduces resting and exercise HR without affecting cardiac contractility or blood pressure. It exerts antianginal and anti-ischemic effects in patients with coronary artery disease. Improved exercise tolerance, increased time to exerciseinduced ischemia, and reduced frequency of ambient anginal attacks have been observed after funny current channel inhibition [2] . 1 . We aimed to evaluate the influence of Ivabradine on long term prevention of major adverse cardiac events (MACE) major adverse cardiac events (MACE) including; death, myocardial infarction, serious arrhythmias, need for urgent revascularization using high sensitivity crp (hs CRP).
Patients
We studied sixty patients admitted to the CCU of critical care department at Cairo University due to acute coronary syndrome over the period of 6 months. All patients gave informed consent, and the protocol was approved by the institutional review board.
Inclusion criteria
Patients with ischemic manifestations suspected to represent ACS (unstable angina). Patients with sinus rhythm whose heart rate was greater than 60 beats per minute on a resting standard 12 lead ECG.
Exclusion criteria Pregnant or breast-feeding women or women of child bearing potential. Patients with acute ST segment elevation or non-ST segment elevation myocardial infarction or those requiring urgent coronary revascularization. Patients with atrial fibrillation or flutter, sick sinus syndrome, sino-atrial block and complete atrio-ventricular block.
Methods
All included patients were subjected to:
Detailed history taking and physical examination: including Laboratory investigations: (cardiac enzymes and troponin i) which were withdrawn on admission and every 6 h thereafter for 24 h then followed up daily for 5 days and when indicated.
High sensitivity C-reactive protein (hs-CRP) (quantitative value) which was done on day of admission and repeated for follow up at day 4 and at day 30 (after withdrawal of study medications) with a normal range <0.5 mg/dl [3] .
Eventually, patients were allocated randomly to the following groups:
Group (A): Included thirty patients who received conventional therapy and ivabradine. Group (B): Included thirty patients who received conventional therapy only.
Patients of both groups received the conventional cardiovascular treatment which included nitrates, maximum tolerated dose of beta blocker (bisoprolol 10 mg/day), statins (atorvastatin 40 mg/day), antiplatelets (ASA 150 mg/day).
Ivabradine administration protocol for patients of group (A): included;
Within 48 h of hospital admission, the starting dose of ivabradine was 5 mg twice daily. After one week, patients with resting heart rate greater than 60 beats per minute received the target dose of 7.5 mg of ivabradine twice daily up to the follow up period of 30 days. cardiac assessment:
Electrocardiography (ECG). Echocardiography (TTE).
Myocardial perfusion imaging (MPI).
Patients were subjected to Technetium 99 sesta MIBI Myocardial perfusion imaging (MPI) within 6-8 h after admission as an acute imaging equivalent to stress MPI then after 4 days as rest MPI and were followed up on day 30 with rest and stress imaging with the same dose of injection using multi-spect Siemens dual head gamma Camera.
Statistical methods
All obtained data were analyzed statistically by SPSS (Statistical Package for Social Science) program.
Results
The mean age of the study group was 53.45 years old. In our study, there were 24 male patients who represented 40% of study population and 36 female patients which represented 60% of study population (see Table 1 ).
Our studied patients' characteristics are summarized in Table 2 .
Myocardial perfusion imaging (MPI)
There were no significant differences between both groups in prevalence of Risk factors; Systemic hypertension (P value 0.430), Diabetes mellitus (P value 0.435), Smoking (P value 0.796), dyslipidemia (P valve 1.0), family history of CAD (P value 0.601) and obesity (P value 0.968). There were no significant differences between both groups in ECG ischemic or dynamic changes (see Tables 3 and 4 ).
Hs-CRP
There were significant differences between both groups in Hs-CRP value on admission and day 4 follow up (P value 0.629, 0.042 respectively). There were no significant differences in Hs-CRP value between admission day and day 4 in patients of group (B) (P value 0.774). There were no significant differences in Hs-CRP value between day 4 and day 30 in patients of group (B) (P value 0.062). There were significant variances in Hs-CRP value at day 4 in both groups; patients in group A showed a statistically significant lower level of hs-CRP at day 4 compared to group B (1 ± 0.4 mg/dl versus 1.3 ± 0.5 mg/dl; P value 0.043).
There were significant variances in Hs-CRP value at day 30 in both groups (P < 0.001). Patients of group A showed statistically significant lower level of hs-CRP at day 30 compared to group B (0.7 ± 0.3 mg/dl versus 1.66 ± 0.9 mg/dl; P value < 0.001). There were significant differences in Hs-CRP value between admission day and day 30 in patients of group (A) (P value < 0.001). Patients of group A showed a significantly lower hs-CRP level at day 30 compared to hs-CRP on admission (0.71 ± 0.28 mg/dl versus 1.32 ± 0.41 mg/ dl; P value < 0.001). There were significant variances in Hs-CRP value between admission day and day 30 in patients of group (B) (P value 0.043). Patients of group B showed a significantly higher hs-CRP level at day 30 compared to admission hs-CRP (1.37 ± 0.38 mg/dl versus 1.66 ± 0.92 mg/dl; P value 0.043). There were significant variances in Hs-CRP value between day 4 and day 30 in patients of group (A) (P value 0.001). Patients of group A showed a significantly lower hs-CRP at day 30 compared to day 4 (0.71 ± 0.28 mg/dl versus 1 ± 0.5 mg/dl; P value 0.001). 
Myocardial perfusion imaging
There were no significant differences between both groups in territorial myocardial perfusion defects (P value 0.668). There were no statistically significant differences in summed stress score (SSS) on admission and on day 30 between both groups (P value 0.894 and 0.194 respectively). There were no statistically significant differences in left ventricular end-systolic volume (LVESV) during stress at day 30 between both groups (P value 0.714) (see Table 5 ).
By following up the trend of hs-CRP quantitative value on day 1, day 4 and day 30 in both groups of patients, we found that those who received ivabradine together with conventional therapy (group A) showed decreasing value of hs-CRP during one month follow up period which was not observed in those who received conventional therapy only without ivabradine (group B) (P value < 0.001).
Mortality data
Although, MACE occurred in 15 patients (25% of study population) during follow up after one month, there was no statistically significant difference between both groups regarding 30 days follow up MACE (P value 0.552).
Discussion
Although serum concentrations of cardiac enzymes are the main diagnostic laboratory investigation of acute coronary syndrome, serum concentration of inflammatory markers has shown in many studies to correlate strongly with cardiovascular mortality & morbidity in patients with acute coronary syndrome [4] .
Measuring serum C-reactive protein level (CRP) with the improved methodology of the highly sensitive assay can identify the risk level for acute coronary syndrome (ACS) [3] .
Ivabradine, a selective inhibitor of the funny current channel, reduces resting and exercise heart rate without affecting cardiac contractility or blood pressure. It exerts antianginal and anti-ischemic effects in patients with coronary artery disease. Improved exercise tolerance and reduced frequency of anginal attacks have been observed after funny current channel inhibition [2] .
Reduced heart rate variability and increased resting heart rate are indicators of sympatho-vagal defect and has been found to be associated with cardiovascular mortality and morbidity in patients with acute coronary syndrome [5] . It has been also shown to be a potent indicator of progression of coronary artery disease [1] . This has been associated with coronary plaque rupture with sub-clinical inflammation and plays a role in the pathogenesis of coronary atherosclerosis [6] .
Through comparison between the two groups of studied patient, Group A who received ivabradine together with conventional anti-ischemic therapy and group B who received conventional anti-ischemic therapy only; there were no significant differences between both groups regarding age, gender, prevalence of risk factors, ischemic ECG changes and hs-CRP level on day of admission (P value > 0.05).
Our current study showed significant variances in hs-CRP value at day 4 and day 30 in both groups, patients of group A showed a statistically significant lower level of hs-CRP at day 4 and day 30 compared to group B (P value 0.043 and <0.001 respectively). Also there were significant differences in Hs-CRP level of group A between admission day and day 30 (P value < 0.001) and between day 4 and day 30 (P value 0.001).Patients of group A showed a significantly lower hs-CRP level at day 30 compared to hs-CRP on admission and on day 4.
In concordance with our findings, a randomized, doubleblind, placebo-controlled trial of ivabradine in patients with NSTE-ACS that was carried out by Alberto et al. in April 2012 and published in June 2012 in the international journal of cardiology. They hypothesized that the addition of ivabradine (a heart rate lowering agent) to standard medical therapy had a beneficial effect on markers of inflammatory stress in acute coronary syndrome patients using high sensitivity Creactive protein as an independent factor for sub-clinical inflammatory state [4] .
In contrast, Alberto et al. disagreed with our study by demonstrating that higher hs-CRP levels were associated with adverse outcomes and that HR reduction with ivabradine has been shown to decrease major adverse cardiovascular events. They stated that this effect was related to decreasing serum levels of markers of vascular oxidative stress, improving 6 1 0 endothelial function and reduced atherosclerotic plaque formation [4] . Supporting our results, the Riviera study, a uni-center, randomized, double-blind, placebo-controlled trial involving 1270 patients admitted with non-ST elevation ACS, hypothesized that early initiation of ivabradine therapy after hospital admission for ACS led to reduction of hs-CRP levels [8] . In contrast, the Riviera study stated that immediate administration of ivabradine therapy after hospital admission for ACS was associated with improvement of cardiovascular outcomes [7] .
Our study showed that there was no statistically significant difference between both groups regarding 30 days follow up MACE (P value 0.552).
These findings agreed with the study of Shavarov et al. that was conducted on 98 unstable angina patients with 14 days follow up and investigated the efficacy of early administration of ivabradin in addition to metoprolol in patients with acute coronary syndrome (unstable angina) compared to the efficacy of administration of metoprolol alone. They concluded that combined treatment with metoprolol and ivabradine showed the same anti-ischemic activity compared with metoprolol regimen in patients with ACS. There were no significant differences in occurrence of major adverse cardiovascular events in both groups of patients (P value 0.14) [8] .
Unfortunately, our study was conducted on sixty patients only, being a self-funding research with lack of the quantitative hs-CRP in our CCU laboratory unit. In addition, our study included follow up of hs-CRP for all studied patients on day 1, at day 4 and at day 30.
The high selectivity of our studied patients limited their number. This was essential for the accuracy of our results. We excluded any patient above the age of 80 years, disseminated malignancies, chronic liver cell failure, patients with chronic renal dialysis, chronic hematological disorders, patients with coagulation defects or receiving anticoagulation therapy, concomitant treatment with carcinostatics or irradiation, post-cardiopulmonary resuscitation status, those whose investigations could not be done or lost, patients transferred to other hospitals, missing values of any included patient.
Finally, concerning the statistically insignificant results concerning the effect of Ivabradine which were observed in our study, it would be better to be revised and re-evaluated again in future studies on a larger number of patients to give more accurate statistical results.
Conclusion
Administration of ivabradine within 48 h of CCU admission decreased hs-CRP level in patients with acute coronary syndrome (unstable angina).but did not decrease the occurrence of major cardiac events in ACS patients.
